Use of circulating tumour DNA to prospectively guide a switch from targeted to immune therapy in BRAF mutant advanced melanoma: the randomised phase II CAcTUS trial.

doi:10.1038/s41467-026-72735-8

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Use of circulating tumour DNA to prospectively guide a switch from targeted to immune therapy in BRAF mutant advanced melanoma: the randomised phase II CAcTUS trial.

Nature communications - 21 May 2026

Lee Rebecca J, Rothwell Dominic G, Smith Nigel, Chow Shien, Delgado-SanMartin Juan, Mistry Hitesh, Sylvestre Yvonne, Chiang Shih-Chieh, Clarke Harry, Gremel Gabriela, Gupta Avinash, Hockenhull Kimberley, Kelso Noel, Kochhar Rohit, Mullan Damian, Plummer Ruth, Serra Patricio, Shaw Heather, Summersgill Holly, Turajlic Samra, Mouliere Florent, Marais Richard, Dive Caroline, Lorigan Paul

Abstract excerpt

Checkpoint inhibitor immunotherapy (CPI) for BRAF mutant advanced melanoma first-line results in a better long-term survival compared to targeted therapy (TT), however TT induction may benefit poor prognosis groups. The parallel-arm, randomised phase II, multicentre, feasibility CAcTUS trial (Clinicaltrials.gov NCT03808441) randomised 21 patients to receive standard of care investigators choice TT or CPI,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Circulating Tumor DNA

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Checkpoint Inhibitors

Share to Immunotherapy

Share to Melanoma

Share to Molecular Targeted Therapy

Share to Mutation

Share to Progression-Free Survival

Share to Proto-Oncogene Proteins B-raf

Source

Open in PubMed Open full text

Identifiers

PMID: 42168180
DOI: 10.1038/s41467-026-72735-8
PMCID: PMC13389006

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Use of circulating tumour DNA to prospectively guide a switch from targeted to immune therapy in BRAF mutant advanced melanoma: the randomised phase II CAcTUS trial.PMID 42168180Read ↗

In-depth assessment of BRAF, NRAS, KRAS, EGFR, and PIK3CA mutations on cell-free DNA in the blood of melanoma patients receiving immune checkpoint inhibitionSemantic proximity Read ↗

Dynamic ctDNA mutational complexity in melanoma patients receiving immunotherapySemantic proximity Read ↗

Circulating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumorsSemantic proximity Read ↗

Dynamic ctDNA Mutational Complexity in Patients with Melanoma Receiving Immunotherapy.Semantic proximity Read ↗

Circulating Tumor DNA (ctDNA) Clearance After Immune Checkpoint Inhibition (ICI) with Radiotherapy (RT) as a Prognostic Biomarker for Advanced MelanomaSemantic proximity Read ↗

Prospective assessment of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafuspSemantic proximity Read ↗

Use of ctDNA in identifying an actionable BRAF mutation in stage 4 metastatic melanoma.Semantic proximity Read ↗

Development of a Nomogram to Predict Therapeutic Resistance in Metastatic Melanoma Using Longitudinal ctDNA Kinetics.Semantic proximity Read ↗

Breaking resistance in BRAF-mutant Melanoma: Novel strategies and biomarkers for optimizing targeted therapies.Semantic proximity Read ↗

Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy.Semantic proximity Read ↗

Tumor-Naïve Circulating Tumor DNA as an Early Response Biomarker for Patients Treated With Immunotherapy in Early Phase Clinical TrialsSemantic proximity Read ↗

Circulating tumor DNA monitoring in advanced mutated melanoma (LIQUID-MEL)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.